| Literature DB >> 36061352 |
Xiao-Cui Liu1, Yu-Ling Dai2, Fei Huang3, Zhen-Jie Zhong4, Xiao-Fei Liu4.
Abstract
Purpose: To evaluate the diagnostic value of carcinoembryonic antigen (CEA) combined with inflammatory cell ratios in colorectal cancer (CRC).Entities:
Mesh:
Substances:
Year: 2022 PMID: 36061352 PMCID: PMC9439887 DOI: 10.1155/2022/4889616
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.464
Clinicopathological features in the cancer and healthy groups.
| Groups | Cancer group | Healthy group |
|
|---|---|---|---|
|
| 324 | 216 | <0.01 |
| CEA (ng/mL) | 14.08 ± 47.94 | 2.21 ± 2.09 | <0.01 |
| NLR | 2.82 ± 1.92 | 1.94 ± 2.13 | <0.01 |
| d-NLR | 2.01 ± 1.33 | 1.36 ± 0.43 | <0.01 |
| PLR | 177.45 ± 89.75 | 135.99 ± 157.94 | <0.01 |
| MLR | 0.30 ± 0.35 | 0.21 ± 0.16 | <0.01 |
CEA: carcinoembryonic antigen; NLR: neutrophil-to-lymphocyte ratio; d-NLR:derived neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; MLR: monocyte-to-lymphocyte ratio.
Figure 1ROC curve analysis of relevant inflammatory indices.
Comparison of ROC curves of relevant inflammatory indices.
| Detection index | Cutoff value | AUC |
| Sensitivity (%) | 95% CI | Specificity (%) | 95% CI |
|---|---|---|---|---|---|---|---|
| NLR | 2.10 | 0.74 | 0.70-0.78 | 78.70 | 0.73-0.84 | 58.33 | 0.53-0.64 |
| d-NLR | 1.73 | 0.71 | 0.67-0.75 | 83.33 | 0.78-0.88 | 50.31 | 0.45-0.56 |
| PLR | 146.71 | 0.75 | 0.72-0.79 | 84.72 | 0.79-0.89 | 57.72 | 0.52-0.63 |
| MLR | 0.22 | 0.68 | 0.64-0.72 | 74.07 | 0.68-0.80 | 54.94 | 0.49-0. 60 |
AUC: area under the curve; CI: confidential interval.
Relationship between preoperative NLR, d-NLR, and PLR and clinicopathological features.
| Variable | Patients ( | NLR | d-NLR | PLR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| >2.10 | ≤2.10 |
| >1.73 | ≤1.73 |
| >146.71 | ≤146.71 |
| ||
| Age (years) | ||||||||||
| ≥60 | 172 | 100 | 72 | 0.96 | 87 | 97 | 0.39 | 96 | 76 | 0.46 |
| <60 | 152 | 88 | 64 | 79 | 73 | 91 | 61 | |||
| Sex | ||||||||||
| Male | 188 | 117 | 71 | 0.07 | 101 | 87 | 0.29 | 104 | 84 | 0.31 |
| Female | 136 | 71 | 65 | 65 | 71 | 83 | 53 | |||
| TNM stage | ||||||||||
| | 218 | 137 | 81 | 0.01 | 99 | 119 | <0.01 | 111 | 107 | <0.01 |
| III + IV | 106 | 51 | 55 | 67 | 39 | 76 | 30 | |||
| Location | ||||||||||
| Colon | 168 | 96 | 72 | 0.74 | 98 | 70 | 0.12 | 93 | 75 | 0.37 |
| Rectum | 156 | 92 | 64 | 68 | 88 | 94 | 62 | |||
| Grade | ||||||||||
| High | 89 | 51 | 38 | 0.89 | 49 | 40 | 0.23 | 56 | 33 | 0.24 |
| Moderate | 123 | 70 | 53 | 67 | 56 | 64 | 59 | |||
| Low | 112 | 67 | 45 | 50 | 62 | 67 | 45 | |||
Figure 2ROC curve analysis of different combined detection schemes.
Comparison of ROC curves of different combined detection schemes.
| Joint indices | Cutoff value | AUC | 95% CI | Sensitivity (%) | 95% CI | Specificity (%) | 95% CI |
|
|---|---|---|---|---|---|---|---|---|
| CEA | 2.63 | 0.75 | 0.71-0.79 | 77.78 | 0.72-0.83 | 64.51 | 0.59-0.70 | <0.01a |
| CEA+PLR | 0.48 | 0.80 | 0.76-0.83 | 68.06 | 0.61-0.74 | 78.40 | 0.74-0.83 | <0.05b |
| CNDNP | 0.61 | 0.74 | 0.70-0.78 | 81.02 | 0.75-0.86 | 58.64 | 0.53-0.64 | <0.01c |
| CEA+CNDNP | 0.52 | 0.83 | 0.79-0.86 | 77.78 | 0.72-0.83 | 72.50 | 0.67-0.77 | <0.01d |
CNDNP: combination of NLR, d-NLR, and PLR. avs. CEA + PLR; bvs. CNDNP; cvs. CEA+ CNDNP; dvs. CEA.